The National Pharmaceutical Pricing Authority (NPPA) on Friday asked the makers of key drugs like FDC Lopinavir and Ritonavir, hydroxychloroquine, azithromycin and paracetamol to submit report abouttheir stock availability with a view to deal with the situation arising out of COVID-19 pandemic.
Invoking powers given under the para 29 - maintenance of records and production thereof for inspection - of the Drug Prices Control Order 2013, the regulatorasked the drug manufacturers of medicines namely FDC Lopinavir and Ritonavir (200mg+50 mg), Hydroxychloroquine 200 mgand 400 mg, Azithromycin 250 mg and 500 mg and Paracetamol 500 mg to submit the information by 6 pm in a prescribed proforma.
It asked the companies to provide details such as their names, installed capacity tablets per day, total stock in-hand in number of tablets, commitment for exports in number of tablets, domestic commitment in number of tablets, currentstock of API in KG,